Strs Ohio Chinook Therapeutics, Inc. Transaction History

Strs Ohio

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 31, 2023	SELL	$18.66 - $38.58 $117,558 - $243,054	-6,300 Reduced 45.32%	7,600 $291,000
Q1 2023 Aug 02, 2023	BUY	$21.53 - $26.8 $135,639 - $168,840	6,300 Added 82.89%	13,900 $321,000
Q3 2022 Oct 27, 2022	BUY	$17.51 - $23.37 $171,598 - $229,026	9,800 Added 239.02%	13,900 $273,000
Q2 2022 Jul 25, 2022	BUY	$12.59 - $18.8 $51,619 - $77,080	4,100 New	4,100 $71,000
Q3 2021 Oct 22, 2021	SELL	$11.5 - $14.86 $83,950 - $108,478	-7,300 Closed	0 $0
Q2 2021 Jul 26, 2021	BUY	$13.6 - $18.98 $55,760 - $77,818	4,100 Added 128.13%	7,300 $103,000
Q4 2020 Jan 25, 2021	BUY	$11.9 - $20.91 $38,080 - $66,912	3,200 New	3,200 $50,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

Stay updated on Strs Ohio with notifications on news.